Innovative Targeted Therapeutics from PhotoBiotics
Bespoke targeting agents for MRI imaging and cancer treatment. We call this OptiLink™
PhotoBiotics Ltd is a multidisciplinary spin-out from Imperial College London UK which combines chemistry, photophysics, and biochemistry ... read more »
Technology / Pipeline
Antibody fragment with PhotoBiotics' Optilink proprietary conjugation technology being used to attach a variety of agents, in this case for phototherapy and MRI diagnosis
Antibody-drug conjugates are expected to be the next generation of antibody therapeutics. Current unmodified monoclonal antibodies (MAbs) do not cure, and can only extend survival by 5-6 months. In addition, many antibodies suffer from drug resistance due to mutations in cell-signalling pathways.
OptiLink™ is a unique and simple conjugation platform for better drug delivery in imaging and therapy. It enables multiple loading of drug molecules and imaging agents onto specifically bio-engineered antibody fragments... read more »
As our pipeline evolves, OptiLink™ will deliver novel targeted 'see and treat' agents to improve efficacy and tolerability of treatment, significantly shorten tumour treatment times, and improve quality of life for patients... read more »